Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.

Cancer chemotherapy and pharmacology - 1 May 2024

Fan Bin, Abou-Alfa Ghassan K, Zhu Andrew X, Pandya Shuchi S, Jia Hongxia, Yin Feng, Gliser Camelia, Hua Zhaowei, Hossain Mohammad, Yang Hua

Abstract excerpt

PURPOSE: Report pharmacokinetic (PK)/pharmacodynamic (PD) findings from the phase III ClarIDHy study and any association between PK/PD parameters and treatment outcomes in this population. METHODS: Patients with mutant isocitrate dehydrogenase 1 (mIDH1) advanced cholangiocarcinoma were randomized at a 2:1 ratio to receive ivosidenib or matched placebo. Crossover from placebo to ivosidenib was permitted at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 38278871
DOI: 10.1007/s00280-023-04633-5
PMCID: PMC11043204

Genes

C3
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.PMID 38278871Read ↗

Ivosidenib: A Review in Advanced Cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Semantic proximity Read ↗

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To DateSemantic proximity Read ↗

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.Semantic proximity Read ↗

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Semantic proximity Read ↗

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.Semantic proximity Read ↗

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.Semantic proximity Read ↗

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.